Coactivator proteins as determinants of estrogen receptor structure and function: spectroscopic evidence for a novel coactivator-stabilized receptor conformation.
The direct regulation of gene transcription by nuclear receptors, such as the estrogen receptor (ER), involves not just ligand and DNA binding but the recruitment of coregulators. Typically, recruitment of p160 coactivator proteins to agonist-liganded ER is considered to be unidirectional, with ligand binding stabilizing an ER ligand binding domain (LBD) conformation that favors coactivator interaction. Using fluorophore-labeled ERalpha-LBDs, we present evidence for a pronounced stabilization of ER conformation that results from coactivator binding, manifest by decreased ER sensitivity to proteases and reduced conformational dynamics, as well as for the formation of a novel coactivator-stabilized (costabilized) receptor conformation, that can be conveniently monitored by the generation of an excimer emission from pyrene-labeled ERalpha-LBDs. This costabilized conformation may embody features required to support ER transcriptional activity. Different classes of coactivator proteins combine with estrogen agonists of different structure to elicit varying degrees of this receptor stabilization, and antagonists and coactivator binding inhibitors disfavor the costabilized conformation. Remarkably, high concentrations of coactivators engender this conformation even in apo- and antagonist-bound ERs (more so with selective ER modulators than with pure antagonists), providing an in vitro model for the development of resistance to hormone therapy in breast cancer.
Tamrazi
Anobel
A
Department of Chemistry, University of Illinois, 600 South Mathews Avenue, Urbana, Illinois 61801, USA.
Carlson
Kathryn E
KE
Rodriguez
Alice L
AL
Katzenellenbogen
John A
JA
D000495:Allosteric Site; D000818:Animals; D016880:Anisotropy; D001703:Biophysics / Q000379:methods*; D001943:Breast Neoplasms / Q000188:drug therapy; D004247:DNA / Q000737:chemistry / Q000378:metabolism; D019281:Dimerization; D019008:Drug Resistance, Neoplasm; D047628:Estrogen Receptor alpha / Q000378:metabolism; D031541:Fluorescence Resonance Energy Transfer; D006801:Humans; D066298:In Vitro Techniques; D008024:Ligands; D008856:Microscopy, Fluorescence; D008956:Models, Chemical; D008958:Models, Molecular; D010447:Peptide Hydrolases / Q000378:metabolism; D010455:Peptides / Q000737:chemistry; D011485:Protein Binding; D011487:Protein Conformation; D017434:Protein Structure, Tertiary; D011960:Receptors, Estrogen / Q000737:chemistry* / Q000378:metabolism; D013050:Spectrometry, Fluorescence; D013329:Structure-Activity Relationship; D013629:Tamoxifen / Q000494:pharmacology; D013997:Time Factors; D014158:Transcription, Genetic; D014357:Trypsin / Q000494:pharmacology
D047628:Estrogen Receptor alpha; D008024:Ligands; D010455:Peptides; D011960:Receptors, Estrogen; D013629:Tamoxifen; D004247:DNA; D010447:Peptide Hydrolases; D014357:Trypsin